ArticleFrontiers in cardiovascular medicine2026
Serum-Amyloid-A to High-Density-Lipoprotein-Cholesterol Ratio: superior biomarker for early diagnosis of coronary artery disease with clinically relevant stenoses and development of machine learning diagnostic model.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to evaluate the early diagnostic value of Serum-Amyloid-A to High-Density-Lipoprotein-Cholesterol Ratio (SHR) for coronary artery disease (CAD) with clinically relevant stenoses and develop a machine learning diagnostic model based on eXtreme Gradient Boosting (XGBoost). Methods and results: Data from 1,108 CAD patients (with coronary luminal diameter stenosis ≥50% or evidence of functional myocardial ischemia) and 962 controls were retrospectively analyzed. Receiver operating characteristic (ROC) analysis showed SHR (area under the curve (AUC) = 0.769) outperformed C-reactive protein (CRP) ( Conclusion: SHR is a superior composite biomarker for early diagnosis of CAD with clinically relevant stenoses, outperforming CRP and SAA. Machine learning model integrating multiple indicators shows excellent diagnostic performance. Elevated SHR indicates higher CAD risk in younger individuals, providing a new strategy for early screening of CAD with clinically relevant stenoses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.